查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1628899

癌胚抗原市场，按性别、按应用、最终用户、按国家和地区划分 - 2024-2032 年行业分析、市场规模、市场份额和预测

Carcinoembryonic Antigen Market, By Gender, By Application, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年癌胚抗原市场规模为22.155亿美元，2024年至2032年复合年增长率为6.50%。

癌胚抗原市场-市场动态

癌症发生率上升

预计癌症病例的增加将推动未来癌胚抗原市场的发展。异常细胞不受控制的发育和扩散是癌症的标誌。由于人口老化、遗传倾向、环境污染物和生活方式的选择，癌症变得越来越普遍。肿瘤标记癌胚抗原（CEA）用于追踪癌症的病程和治疗效果。例如，总部位于美国的政府间机构世界卫生组织 (WHO) 在 2024 年 2 月表示，预计 2050 年将出现约 3,500 万新发癌症病例，比 2019 年预测的 2,000 万例增加 77%。因此，由于癌症发生率的增加，癌胚抗原市场正在扩大。

癌胚抗原市场-关键见解

根据我们的研究分析师分享的分析，预计全球癌胚抗原市场在预测期内（2024-2032）每年将以 6.50% 左右的复合年增长率成长

根据性别细分，预计男性类别将在 2023 年显示最大的市场份额

从应用细分来看，2023年胃肠癌是主导细分领域

按地区划分，北美是 2023 年的主要收入来源

癌胚抗原市场-細項分析：

全球癌胚抗原市场根据性别、应用、最终用户和地区进行细分。

依应用，市场分为肺癌、胃肠道癌（大肠癌、食道癌、肝癌、胰臟癌、胃癌、肛门癌、胆囊癌）、乳癌、卵巢癌、摄护腺癌和甲状腺癌。 2023年，市场以胃肠道癌症类别为主。在全球范围内，结肠癌、胃癌和胰腺癌是最常见的肠癌类型。其高盛行率和侵袭性推动了对有效诊断和监测方法的需求，而 CEA 是这些疾病的关键生物标记。此外，由于风险随着年龄的增长而增加，人口老化——特别是在已开发地区——导致胃肠道恶性肿瘤盛行率增加。这种人口趋势进一步增加了对 CEA 检测的需求，这进一步巩固了胃肠道癌症领域的相关性。

癌胚抗原市场分为最终用户部分，包括医院、肿瘤诊所、诊断实验室、研究中心和学术机构。 2023 年医院部门的收入为。癌症诊断、治疗和监测的主要地点是医院，通常使用 CEA 检测。由于全球癌症发生率不断上升，对监测和诊断工具的需求增加，医院对 CEA 检测的使用不断增加。医院经常使用经过训练的工作人员和尖端的诊断工具，进一步促进了 CEA 检测的准确和有效使用。对癌症患者的常规医院监测和早期发现的关注有助于该细分市场的成长。

癌胚抗原市场-地理洞察

从地理来看，癌胚抗原市场广泛分布于北美、拉丁美洲、欧洲、亚太地区、中东和非洲地区。这些区域根据开展业务的国家进一步划分。

由于北美地区癌症发生率高、医疗保健系统完善以及研发支出庞大，该地区的癌胚抗原市场在全球占据主导地位。由于早期癌症识别和监测对于成功治疗至关重要，因此该地区的市场正在不断增长。美国癌症协会预计，到 2023 年，北美将诊断出 190 万新癌症病例。由于发生率高，CEA 和其他肿瘤标记的需求量很大。此外，许多主要的诊断公司，例如雅培实验室和罗氏诊断公司，都总部位于北美，并不断开发和扩大其产品线以满足不断增长的需求。

然而，未来几年，由于癌症盛行率上升、医疗成本上升以及早期癌症检测意识增强等因素，亚太地区癌胚抗原市场预计将大幅成长。中国、印度和日本由于人口众多且癌症发生率较高，因此处于这一扩张的最前线。根据国际癌症研究机构 (IARC) 的数据，2020 年，亚洲约占全球所有癌症病例的 49.3%。进一步推动该地区市场扩张的是政府加强医疗设施和鼓励早期诊断检测（例如 CEA）的计划。

癌胚抗原市场-竞争格局：

癌胚抗原市场是由主要公司之间的激烈竞争推动的，包括 Quest Diagnostics、Thermo Fisher Scientific Inc.、Boster Biological Technology、Abcam Limited、Creative Diagnostics 和 F. Hoffmann-La Roche Ltd 等。这些公司投资于研发，以提高癌胚抗原测试的精确度和可负担性，同时利用其广泛的产品组合和强大的分销网络。透过免疫测定和即时诊断的进步，新兴企业也正在推动该产业的发展。此外，技术发展以及对早期癌症检测和监测的日益重视正在推动市场需求，并为老牌和新兴竞争对手打开大门。例如，2023 年 12 月，赛诺菲暂停了 tusamitamab ravtansine 的全球科学开发计画。 3 期 CARMEN-LC03 试验是这项决定的来源，该试验评估了 tusamitamab ravtansine 作为单一疗法与多西他赛对已接受治疗的转移性非鳞状非小细胞肺癌 (NSCLC) 患者的治疗效果。

最新进展：

2024 年4 月：着名的AI TechBio 业务和精准医疗先驱Caris DiscoveryTM（Caris Life Sciences(R) (Caris) 的研究部门）宣布与总部位于德国达姆施塔特的默克公司建立长期战略合作伙伴关係。在美国和加拿大，以 EMD Serono 为名经营医疗保健业务的 Merck KGaA 将与 Caris DiscoveryTM 合作，加速为癌症患者寻找和开发优质抗体药物偶联物 (ADC)。

2024 年3 月：FDA 指定A2 Biotherapeutics Inc. 为A2B530 的孤儿药，A2B530 是一种新型细胞疗法，旨在治疗生殖系杂合HLA-A02 阳性且肿瘤表达CEA 但不再表达HLA-A02 的结直肠癌患者。这一称号鼓励了药物的开发。它透过强调大肠直肠癌解决这一特定患者群体中未满足的主要需求的潜力，为结直肠癌治疗的进展提供激励。

2023 年7 月：为了同时独立地从单一人血浆或血液样本中确定丙型肝炎病毒(HCV) 抗原和抗体状态，罗氏诊断印度公司推出了Elecsys HCV Duo，这是该国首个完全自动化的免疫测定法。这种创新的诊断技术简化了医疗专业人员的程序并改善了患者的治疗结果，代表了 HCV 识别的重大进步。

目录

第一章：癌胚抗原市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按性别分類的癌胚抗原市场片段
    • 按应用分類的癌胚抗原市场片段
    • 最终用户的癌胚抗原市场片段
    • 按国家/地区分類的癌胚抗原市场片段
    • 按地区分類的癌胚抗原市场片段
  • 竞争洞察

第 3 章：癌胚抗原主要市场趋势

  • 癌胚抗原市场驱动因素
    • 市场驱动因素的影响分析
  • 癌胚抗原市场限制
    • 市场限制影响分析
  • 癌胚抗原市场机会
  • 癌胚抗原市场未来趋势

第 4 章：癌胚抗原产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：癌胚抗原市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：癌胚抗原市场格局

  • 2023 年癌胚抗原市场占有率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：癌胚抗原市场 - 按性别

  • 概述
    • 按性别分類的细分市场占有率分析
    • 男性
    • 女性

第 8 章：癌胚抗原市场 - 按应用

  • 概述
    • 按应用分類的细分市场占有率分析
    • 肺癌
    • 胃肠癌
      • 大肠直肠癌
      • 食道癌
      • 肝癌
      • 胰腺癌
      • 胃癌
      • 肛门癌
      • 胆囊癌
    • 乳癌
    • 卵巢癌
    • 摄护腺癌
    • 甲状腺癌

第 9 章：癌胚抗原市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 肿瘤诊所
    • 诊断实验室
    • 研究中心和学术机构

第 10 章：癌胚抗原市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美癌胚抗原主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模与预测（按性别）
    • 北美市场规模和预测（按应用）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲癌胚抗原主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按性别）
    • 欧洲市场规模和预测（按应用）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区癌胚抗原主要生产商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（依性别）
    • 亚太地区市场规模与预测（按应用）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 韩国
    • 日本
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲癌胚抗原主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按性别）
    • 拉丁美洲市场规模与预测（按应用）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲癌胚抗原主要生产商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按性别）
    • 中东和非洲市场规模及预测（按应用）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析-癌胚抗原产业

  • 竞争仪表板
  • 公司简介
    • Boster Biological Technology
    • Abcam Limited
    • Creative Diagnostics
    • Aviva Systems Biology Corporation
    • AdvaCare Pharma
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • Omega Diagnostics Ltd.
    • Medix Biochemica
    • RayBiotech, Inc.
    • Diazyme Laboratories Inc.
    • Quest Diagnostics Incorporated
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4432

REPORT HIGHLIGHT

Carcinoembryonic Antigen Market size was valued at USD 2,215.5 Million in 2023, expanding at a CAGR of 6.50% from 2024 to 2032.

The endodermal epithelial cells of the embryo contain carcinoembryonic antigen (CEA). The fluids of the fetus, embryo, and gastrointestinal tract contain a glycoprotein called carcinoembryonic antigen. Carcinoembryonic antigen is also present in trace amounts in the blood, gastrointestinal cells, and colon mucosal cells. Additionally, the test can be used to diagnose and treat cancers like ovarian, lung, liver, colorectal, gastrointestinal, or colon cancers, as well as breast cancer. The market is expected to rise as a result of rising cancer incidence, an ageing population, and increased awareness. Over the past ten years, there has been a notable increase in the yearly number of cancer diagnoses worldwide. Additionally, as life expectancy rises, more people will receive a diagnosis during their lifetime, which will fuel market expansion.

Carcinoembryonic Antigen Market- Market Dynamics

Rising Incidence of Cancer

It is anticipated that the rising cases of cancer will fuel the market for carcinoembryonic antigens in the future. Uncontrolled development and spread of aberrant cells is a hallmark of cancer. Cancer is becoming common as a result of ageing populations, genetic predispositions, environmental pollutants, and lifestyle choices. The tumour marker carcinoembryonic antigen (CEA) is used to track the course of cancer and the efficacy of treatment. For instance, the World Health Organization (WHO), an intergovernmental agency based in the United States, stated in February 2024 that around 35 million new cases of cancer are expected to occur in 2050, a 77% increase from the 20 million cases forecast in 2022. Thus, the carcinoembryonic antigen market is expanding due to the increase in cancer incidence.

Carcinoembryonic Antigen Market- Key Insights

As per the analysis shared by our research analyst, the global Carcinoembryonic Antigen Market is estimated to grow annually at a CAGR of around 6.50% over the forecast period (2024-2032)

Based on gender segmentation, the male category was predicted to show the maximum market share in the year 2023

Based on application segmentation, the gastrointestinal cancer was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Carcinoembryonic Antigen Market- Segmentation Analysis:

The Global Carcinoembryonic Antigen Market is segmented on the basis of Gender, Application, End-user, and Region.

By application, the market is divided into Lung cancer, Gastrointestinal cancer (Colorectal cancer, Esophageal cancer, Liver cancer, Pancreatic cancer, Stomach cancer, Anal cancer, Gall bladder cancer), Breast cancer, Ovarian cancer, Prostate cancer, and Thyroid cancer. In 2023, the market was dominated by the gastrointestinal cancer category. Globally, colon, stomach, and pancreatic cancers are among the most common types of intestinal cancers. The need for efficient diagnostic and monitoring methods is fueled by their high prevalence and aggressive nature, with CEA acting as a crucial biomarker for these disorders. Furthermore, because the risk increases with age, the ageing population-especially in developed regions-contributes to the increased prevalence of gastrointestinal malignancies. The demand for CEA testing is further increased by this demographic trend, which further solidifies the gastrointestinal cancer segment's relevance.

The market for carcinoembryonic antigens is divided into end-user segments, including Hospitals, Oncology clinics, Diagnostic laboratories, Research centres and academic institutes. Revenue for the hospitals' segment in 2023 was. The main locations for cancer diagnosis, treatment, and surveillance are hospitals, where CEA testing is commonly used. Hospital usage of CEA tests is increasing as a result of the increased demand for monitoring and diagnostic tools due to the rising incidence of cancer worldwide. The accurate and effective use of CEA testing is further facilitated by hospitals' frequent access to trained staff and cutting-edge diagnostic tools. The focus on routine hospital monitoring and early detection of cancer patients contributes to the segment's growth.

Carcinoembryonic Antigen Market- Geographical Insights

Geographically, the Carcinoembryonic Antigen Market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

The market for carcinoembryonic antigen in North America is dominated worldwide due to the region's high cancer incidence, sophisticated healthcare system, and significant R&D expenditures. Due to the fact that early cancer identification and monitoring are essential for successful treatment, the market in this region is growing. In 2023, the American Cancer Society projected that 1.9 million new cases of cancer will be diagnosed in North America. CEA and other tumour markers are in high demand due to this high incidence rate. Furthermore, a number of major diagnostics companies, such as Abbott Laboratories and Roche Diagnostics, are based in North America and are constantly developing and broadening their product lines to meet this rising demand.

However, over the upcoming years, the carcinoembryonic antigen market in the Asia-Pacific region is expected to rise significantly due to factors such as rising cancer prevalence, rising healthcare costs, and increased awareness of early cancer detection. China, India, and Japan are at the forefront of this expansion because of their sizable populations and greater rates of cancer. In 2020, Asia accounted for around 49.3% of all cancer cases worldwide, as per the International Agency for Research on Cancer (IARC). Further driving market expansion in the area are government programs to enhance healthcare facilities and encourage early diagnostic testing, such as CEA.

Carcinoembryonic Antigen Market- Competitive Landscape:

The carcinoembryonic antigen market is driven by fierce competition between major firms, including Quest Diagnostics, Thermo Fisher Scientific Inc., Boster Biological Technology, Abcam Limited, Creative Diagnostics, and F. Hoffmann-La Roche Ltd, among others. These companies invest in R&D to improve the precision and affordability of carcinoembryonic antigen tests while utilizing their broad portfolios and robust distribution networks. Through advancements in immunoassays and point-of-care diagnostics, emerging businesses are also boosting the industry. Furthermore, technical developments and the growing emphasis on early cancer detection and monitoring are driving market demand and opening doors for both established and up-and-coming competitors. For instance, in December 2023, the global scientific development project for tusamitamab ravtansine is being halted by Sanofi. The Phase 3 CARMEN-LC03 trial, which evaluates tusamitamab ravtansine as a monotherapy in comparison to docetaxel in patients with metastatic non-squamous non-small cellular lung cancer (NSCLC) who have already received treatment, is the source of this decision.

Recent Developments:

April 2024: The renowned AI TechBio business and precision medicine pioneer Caris DiscoveryTM, the research arm of Caris Life Sciences(R) (Caris), announced a long-term strategic partnership with Merck KGaA, headquartered in Darmstadt, Germany. In the United States and Canada, Merck KGaA, which operates its healthcare business under the name EMD Serono, will partner with Caris DiscoveryTM to accelerate the search for and development of superior antibody-drug conjugates (ADC) for cancer patients.

March 2024: The FDA designated A2 Biotherapeutics Inc. as an orphan medication for A2B530, a new cell therapy designed to treat colorectal cancer in patients with germline heterozygous HLA-A02 positivity whose tumours express CEA but no longer express HLA-A02. This designation encourages the development of the medication. It provides incentives for progress in the treatment of colorectal cancer by highlighting its potential to address a major unmet need in this particular patient population.

July 2023: To determine the hepatitis C virus (HCV) antigen and antibody status simultaneously and independently from a single human plasma or blood sample, Roche Diagnostics India introduced the Elecsys HCV Duo, the country's first completely automated immunoassay. This innovative diagnostic technology simplifies the procedure for medical professionals and improves patient outcomes, representing a major advancement in HCV identification.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Boster Biological Technology
  • Abcam Limited
  • Creative Diagnostics
  • Aviva Systems Biology Corporation
  • AdvaCare Pharma
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Omega Diagnostics Ltd.
  • Medix Biochemica
  • RayBiotech, Inc.
  • Diazyme Laboratories Inc.
  • Quest Diagnostics Incorporated
  • Others

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY GENDER- MARKET ANALYSIS, 2019 - 2032

  • Male
  • Female

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Lung cancer
  • Gastrointestinal cancer
  • Colorectal cancer
  • Esophageal cancer
  • Liver cancer
  • Pancreatic cancer
  • Stomach cancer
  • Anal cancer
  • Gall bladder cancer
  • Breast cancer
  • Ovarian cancer
  • Prostate cancer
  • Thyroid cancer

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Oncology clinics
  • Diagnostic laboratories
  • Research centres and academic institutes

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Carcinoembryonic Antigen Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Carcinoembryonic Antigen Market Snippet by Gender
    • 2.1.2. Carcinoembryonic Antigen Market Snippet by Application
    • 2.1.3. Carcinoembryonic Antigen Market Snippet by End-user
    • 2.1.4. Carcinoembryonic Antigen Market Snippet by Country
    • 2.1.5. Carcinoembryonic Antigen Market Snippet by Region
  • 2.2. Competitive Insights

3. Carcinoembryonic Antigen Key Market Trends

  • 3.1. Carcinoembryonic Antigen Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Carcinoembryonic Antigen Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Carcinoembryonic Antigen Market Opportunities
  • 3.4. Carcinoembryonic Antigen Market Future Trends

4. Carcinoembryonic Antigen Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Carcinoembryonic Antigen Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Carcinoembryonic Antigen Market Landscape

  • 6.1. Carcinoembryonic Antigen Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Carcinoembryonic Antigen Market - By Gender

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Gender, 2023 & 2032 (%)
    • 7.1.2. Male
    • 7.1.3. Female

8. Carcinoembryonic Antigen Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 8.1.2. Lung cancer
    • 8.1.3. Gastrointestinal cancer
      • 8.1.3.1. Colorectal cancer
      • 8.1.3.2. Esophageal cancer
      • 8.1.3.3. Liver cancer
      • 8.1.3.4. Pancreatic cancer
      • 8.1.3.5. Stomach cancer
      • 8.1.3.6. Anal cancer
      • 8.1.3.7. Gall bladder cancer
    • 8.1.4. Breast cancer
    • 8.1.5. Ovarian cancer
    • 8.1.6. Prostate cancer
    • 8.1.7. Thyroid cancer

9. Carcinoembryonic Antigen Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Oncology clinics
    • 9.1.4. Diagnostic laboratories
    • 9.1.5. Research centres and academic institutes

10. Carcinoembryonic Antigen Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Carcinoembryonic Antigen Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Carcinoembryonic Antigen Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Carcinoembryonic Antigen Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Carcinoembryonic Antigen Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Carcinoembryonic Antigen Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Carcinoembryonic Antigen Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Boster Biological Technology
    • 11.2.2. Abcam Limited
    • 11.2.3. Creative Diagnostics
    • 11.2.4. Aviva Systems Biology Corporation
    • 11.2.5. AdvaCare Pharma
    • 11.2.6. F. Hoffmann-La Roche Ltd.
    • 11.2.7. Thermo Fisher Scientific Inc.
    • 11.2.8. Omega Diagnostics Ltd.
    • 11.2.9. Medix Biochemica
    • 11.2.10. RayBiotech, Inc.
    • 11.2.11. Diazyme Laboratories Inc.
    • 11.2.12. Quest Diagnostics Incorporated
    • 11.2.13. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us